Document is current
Any future updates will be listed below
-
Authors
Ventorp, Filip https://orcid.org/0000-0003-1544-2429
Asp, Marie
Olsson, Sofia https://orcid.org/0009-0008-0432-5554
Lindahl, Jesper https://orcid.org/0000-0002-0335-8046
Möller, Stefan https://orcid.org/0000-0001-9144-4077
Svensson, Martina https://orcid.org/0000-0002-2620-5499
Ängeby, Filip https://orcid.org/0009-0009-2681-5447
Pravdinske, Armida
Tjernberg, Johanna https://orcid.org/0009-0007-6704-4015
Schrey, Susann
Ståhl, Darya
Magnusson, Viktor https://orcid.org/0009-0008-3180-3881
Eliasson, Emilia https://orcid.org/0009-0003-7265-2438
Agelii-Weber, Anna
Stålhammar, Erika https://orcid.org/0009-0008-7224-3999
van Westen, Danielle https://orcid.org/0000-0001-8649-9874
Deierborg, Tomas https://orcid.org/0000-0002-3651-3444
Månsson, Kristoffer N. T. https://orcid.org/0000-0002-7796-8445
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Hammar, Åsa
Tornberg, Åsa B. https://orcid.org/0000-0001-5617-0728
Björkstrand, Johannes
Lindqvist, Daniel https://orcid.org/0000-0002-3472-327X
- License Information
-
More Information
Article History
Received: 17 October 2025
Accepted: 13 May 2026
First Online: 12 June 2026
Competing interests
: D.L. has received speaking honoraria from H. Lundbeck AB and Janssen-Cilag AB and has an ongoing collaboration with HMNC Brain Health. M.A. has received speaking honoraria from H. Lundbeck AB. Over the past 3 years, D.A.P. has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Circular Genomics, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences and Neuroscience Software; he has received honoraria from the American Psychological Association, the Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, the Brain and Behavior Research Foundation, the Dana Foundation, Millennium Pharmaceuticals, the National Institute of Mental Health and Wellcome Leap; and he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics and Neuroscience Software. The other authors declare no competing interests. All views expressed are solely those of the authors.
